drugset / Trial / NCT03695757

Development of a New Immunotherapy Using Intramuscular Administration of Autologous Total IgG

NCT03695757 ↗

Phase 1/2 Completed 24 enrolled Ajou University School of Medicine
Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this prospective pilot clinical study is to evaluate the safety and immunostimulatory effect of intramuscularly administrations of autologous total IgG (autologous total IgG therapy) in healthy subjects and patients with advanced solid tumor (non-small cell lung cancer, stomach cancer, colon cancer, ovarian cancer, breast cancer, pancreatic cancer, biliary cancer, melanoma, renal cell carcinoma etc.). In addition, antitumor effect of intramuscularly administrations of autologous total IgG in patients with advanced solid tumor will be also evaluated.

Timeline

Start
2018-11-06
Primary completion
2021-01-26
Completion
2021-03-24

Drugs

EvaluationDrugModalityDoseRoute
Subject autologous total IgG Protein / enzyme biologic 50 mg Intramuscular

Indications

No indication recorded.